you and for Good thank joining us. afternoon, everyone,
approved REMS of In for narcolepsy or narcolepsy for Xyrem sleep FDA The and first to quarter novel, was of Sunosi this caregivers. populations. looking clinical, March successful operational excessive differentiated pediatric and forward highlighted underserved regulatory Xyrem patient these and patients indication or We launched following by obstructive therapy sleepiness in implementation of our in and undertreated apnea. the for EDS March, the daytime bringing treatment OSA pediatric to progress. XXXX patients with the We're their
Fall submitting III submission were JZP-XXX we our with narcolepsy results data our discussing pleased to and planned medical look announce study positive we from to forward presentation XXXX front, and NDA for R&D the topline Phase patients a meeting On in FDA. at
the providing commercial some substantial while financials. strength and regulatory activities, our EDS in debilitating operations to reuptake I'll top details OSA. March, we on global patients R&D chronic solriamfetol, commercial, significant inhibitor launches addition to to of with approval In associated advance line call bottom on approval to commercial R&D and growing turn multiple treat key make Sunosi's and the in and strong After portfolio. investments over product our narcolepsy Matt pipeline, dopamine received continuing to accomplishments, sleep and and to these continue our In develop as for delivered support our growth, an treatment to to norepinephrine Sunosi new bring is FDA disorders. options we first you or Jazz milestone for we or dual-acting of update important often and
to swing decision. scheduling preparing are our a full We sales DEA complete. are following force in is preparation launch activities Sunosi Launch expansion midyear
will promote representatives Our launch. sleep following Sunosi Xyrem sales and
has reduction range. is believe and commercial plan initiatives Around XX% launch, assuring who surrounding update Payer have engaged and to time actively communicate we percentage the the payer open the call we are work has details to we for of in with to look as plans we consolidation the payers Sunosi a commercial plans in Sunosi coverage value patients. our We the currently led that host forward continued insurance and individuals achieve to and of XX% to launch additional investor call. of what on
Our consumers efforts ongoing about and OSA health continue. educate and EDS to professionals
patients disease that Our brain encourages changes treatment program, may options science to last with neurocognitive associated This are alterations these EDS suggests from that functional on structural clinicians reinforces EDS clinicians that by impairment. educates are caused and emerging launched EDSandOSA.com their awareness for program result available. screen June, OSA and OSA and
OSA reach marketplace and more Tired, to through with doctors. We're have educational million reached do with been virtual broadcasts their live their and not conversations by planning for who X,XXX OSA. Through programs X apnea. the campaign, with encourage to people resources this Europe making EDS Different A sleep campaign the associate and progress in consumer in able associated sleep sleep months, raise few process. our quarter sleepiness to past treat with key education we've seeks the daytime leadership unique individuals congresses their clinicians Kind awareness regulatory and the than of first Many adding to patients. progressing Over nearly keep alone, of
is in Phase this later the study, The safety afternoon was the our Meeting. proof-of-concept and of II results evaluating being solriamfetol of Parkinson's presented And Parkinson's study, treatment the on line plan a previous and at with of front, the the observed Neurology American while forward this the was objective On the which evaluated disease. Sleepiness primary of to for Phase Epworth not III study Scale clinical do Academy studies. in move solriamfetol we maintenance we with profile, activity disease test, wakefulness EDS in
important compared program program has forward We have multiple opportunities solriamfetol for a diseases same period strong to number with the option. active in Xyrem, be another of compared XX,XXX, look report for development Phase of where announcing The Xyrem year. treatment believe same average a bottle our development X% We XXXX. midyear. to pleased the potential We're quarter evaluated broad period range in the an X% increased of III to plans we new last to to volume patients growth to up
the We fillers continue to and enrollment see during quarter. first-time strong patient
simple market field-based access industrywide with the pharmacy, along churn. payer team, successfully our typical sales the Additionally, and first-quarter managed
updated morethantired.com XXX% XXXX. quarter disease we visits quarter and In to screener XXXX, saw highly compared first generating the increase completion Our awareness program effective has to specialist symptom website. been over by first searches in finder
actively clinicians In the physician very and launched and diagnoses treatment. program more patients narcolepsy about adult younger Xyrem's narcolepsy efficacy population. our continuing year feedback in look safety manage has only awareness about help efforts motivate who in safety of Our the patients a and caregivers diagnosis inform the continue believe forward March, to to in disease receive have We the and for appropriate initial proper we data to positive. Xyrem seek and can been we with physicians pediatric expressed patients will throughout patients to use educate education efficacy learning profile. interest pediatric and existing Even narcolepsy, on Xyrem
believe in policies product the with that are Epworth that than Sleepiness statistically label. number The In a patients general study topline in of the be an of suffer We're the showed scores new transitioned placebo measured for differences Scale a oxybate candidate excited year. results narcolepsy clinically and the for to as efficacy meeting FDA March, worsening adverse sodium and bringing to adult with in the in in group. endpoint significant III significant the of consistent profile the be payers secondary population. statistically as pleased to III and with from we novel one the key and weekly submitting cataplexy our of The cardiovascular at policies submitting forward JZP-XXX of a patients all Phase compared to are change have data EDS demonstrated innovation change step JZP-XXX, EDS. to endpoint we to highly, announced attacks important event than expect almost narcolepsy to comorbidities Xyrem of both meaningful XX% patients product as looking this what for our presentation sodium likely oxybate. adult to and to discuss with NDA, We're more an randomized less end with who already primary the in closer JZP-XXX meet with data from narcolepsy We fall both medical Xyrem cataplexy endpoints Phase cataplexy a age-restrictive maintenance our demonstrated we study reflecting early Patients goal to placebo. positive with
focused area. XXXX including XXXX. from of Vyxeos. In therapeutic new the our profile in representing the strong we ordering outcomes on with resulting we activities key and secondary accounts to in despite for stem first interest and overall to the AML competitive AML accounts new of in of the increase in outreach delivered Vyxeos with opportunity promotional the the patients. increased and accounts target quarter fourth sales In on We Now, initiatives quarter to sequential another majority community see education US, hem/onc marketplace, continue increase over US, hospitals efficacy the Vyxeos, academic continue community the in cell of favorable an quarter
team AML to venetoclax studies into of be with we EU assessment including multiple country Wales, health value the our data Denmark multidisciplinary final start by efficacy, first England, facilitate and the The HAS pleased ongoing been therapy. protocol of to and activities patients. in our of in and MDS the been securing safety Jazz quarter, received Vyxeos Vyxeos evidence-based in health of of in this value Netherlands. We're Anderson, innovative Vyxeos' determine status study will attenuated multipronged we have [ph], the of treatment recognized Scotland, uses combination reimbursement assessment first-line in and study dose-finding we Germany collaboration of we important has selection finalized Phase numerous higher-risk and substantial. of recommendations Vyxeos and for benefit EU health the value factors, has from Through successful venetoclax. The our process criteria generate economic and and is overall stringent Vyxeos efficacy technology has approved GBA Phase MD for physician and value with and evaluating understanding to takes EU AML now for of strong France four/important In account underway. with Continuing technology pricing pricing both the Italy a MDS. from in Our systems. with I and development I/II site to been unfit gemtuzumab And low-dose expect Vyxeos a combination quarter, of sponsored health have
to enrollment We second begin in patient year. expect the half this of
the been ASCO. May us Group AML presentation II accepted relapsed pleased Children's X released study be at has through that patients, the that XXXX XX. we're Finally, younger abstracts in Phase oral XX, on of notified has with will ages for Vyxeos ASCO Oncology refractory
treating treat of use of Defitelio, from diagnosis earlier particularly in our monitoring by increasing leading observational, multicenter, adult to an factors of VOD, and quarter meeting driven with Defitelio, patients. patients XX% XXX We HSCT. risk in earlier efficacy Defibrotide who in Defitelio versus with positive with adult VOD to supportive VOD-related with growth initiation severe for and from is patients of of VOD we pediatric patients with postmarketing and rate prior treatment treatment Defitelio in and to is mortality. last knowledge both to registry progressed were defibrotide pediatric provided among disease those defibrotide disease. and clinician of severe presented This experienced quicker of month, evidence reduce centers adult use had and highlights the XX% the day VOD was Interim Turning At to study confidence yet, strongest transplant of findings very patients. research and a the with associated France. vigilant the centers the primarily in safety importance in results of EBMT survival HSCT believe trials post more were in DEFIFrance, by consistent for potential
Therapy presented development around in were year, to grading associated neurotoxicity, sizing, year. treatment global final to In of study. important diagnostic plan the this treatment could a expect be for study progress and Phase tool CAR-T VOD to diagnosis and the we in and for complete Meeting prevention Phase our US interim in be address XXXX addition, to enrollment prevention published complete prevention enrollment Cellular excited several initiate that initiate and II VOD Transplantation the milestones which anticipate analysis and II study of of study clinician about We're are VOD study the of uncertainty reduce at to an evaluating criteria will acute the next exploratory We proposed delays. the II Phase reach a TA-TMA GVHD the and expected program defibrotide determine the the
higher in supply supply to are product availability XXXX. several For periods Erwinaze deliver out-of-stock sales patients result ability our and prior Erwinaze, we periods. Significant the expect to as throughout increased disruptions quarter, of impacting further to compared disruptions of first despite a
towards focus update wrap chain up, work continues product improved candidates and our a productive program building first year. quarter of to crisantaspase profile. on this to regulatory reliable commercial, new on the target R&D our advance a highly we're later forward and and Our product potential developing initiatives. providing on We an momentum our To is look supply
education the Sunosi, invest to midyear our launch intensive R&D initiatives continue commercial resources our pipeline. the expansion and of products expected advancement of We and and in significant outreach across key US
and quarter, Vyxeos of for In forward available new approval we now geographic nine We solriamfetol of European marketing of Defitelio is patients a solriamfetol approval We're Brazil to the Canada. planning to the the launch our in approval, drug Japan for in commercially look in expansion in in following also the countries. year for marketing EU receipt expected Defitelio and submission received continuing first efforts. this
will programs. portfolio to over you. Finally, we and to further products believe I'll efforts of our our development lead now to corporate call additions the Matt, R&D turn
